anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
A system collects first data associated with user. The first data includes historical health data and set of sensor data corresponding to a set of health-monitoring parameters. The system applies first Artificial Intelligence (AI) model on the first data to compute indicators which reflect a deviation in a health condition of the user with respect to reference values. Based on the indicators, the system generates first inference data comprising labels or tags associated with a cause of the deviation. Based on the first inference data, the system determines a first requirement for which the user is required to visit a first healthcare center. The system further determines a first set of user-related data associated with the first requirement, based on the first data and the first inference data. Thereafter, the system transfers the first set of user-related data to an electronic healthcare system associated with the first healthcare center.
Parkinson's disease, a progressive neurodegenerative disorder, involves gradual degeneration of the nigrostriatal dopaminergic pathway, leading to neuronal loss within the substantia nigra pars compacta and dopamine depletion. Molecular factors, including neuroinflammation, impaired protein homeostasis, and mitochondrial dysfunction, contribute to the neuronal loss. Deep brain stimulation, a form of neuromodulation, applies electric current through stereotactically implanted electrodes, effectively managing motor symptoms in advanced Parkinson's disease patients. Deep brain stimulation exerts intricate effects on neuronal systems, encompassing alterations in neurotransmitter dynamics, microenvironment restoration, neurogenesis, synaptogenesis, and neuroprotection. Contrary to initial concerns, deep brain stimulation demonstrates antiinflammatory effects, influencing cytokine release, glial activation, and neuronal survival. This review investigates the intricacies of deep brain stimulation mechanisms, including insertional effects, histological changes, and glial responses, and sheds light on the complex interplay between electrodes, stimulation, and the brain. This exploration delves into understanding the role of neuroinflammatory pathways and the effects of deep brain stimulation in the context of Parkinson's disease, providing insights into its neuroprotective capabilities.
Cross-cultural adaptation of a subjective questionnaire is required for use in a different country, culture, and/or language. Although the majority of questionnaires were created in English-speaking nations, researchers must nonetheless take into account non-native populations in health studies, particularly when their omission could result in a systematic bias in studies of health care usage (Beaton et al., 2000). For the purpose of translating and culturally adapting, it is crucial to achieve equality between the target and original sources of the questionnaire.

As it relates to the authors' perspective, the Short Form 36 (SF-36) has not yet been translated and cross-culturally adapted to be used in Myanmar. As a result, the features of a Burmese version's reliability and validity among individuals with a history of stroke have not been studied in the previous research work. In addition, the questionnaire should also be tested for its responsiveness to provide clinical meaningful for health care professions. Therefore, the aim of this study is to develop a Burmese version of the SF-36 (SF-36-Burmese) according to translation and cross-cultural adaption guidelines and evaluate its reliability, validity, and responsiveness (i.e., the instrument's capacity to identify changes over time in the construct being assessed) and the minimum clinical important difference (MCID, ie., the smallest change in an outcome that a patient would perceive as clinically meaningful) among stroke survivors.
Intervention delivered in early pregnancy during an existing antenatal appointment. 1:1 intervention session (15-20 minutes) with the intervention facilitator (clinician/researcher). Participants provided with a self-guided leaflet for weight management focusing on making 10 simple diet and activity behaviours habitual, including advice on food choice \& purchasing, portion size, eating behaviour \& keeping active. The tips promote habit formation, nutrition awareness, avoidance of behavioural relapse, and reiterate guidance for pregnant women. Participants provided with a record-keeping logbook and access to an 'app' to self-monitor their weight and behaviours against the 10 target behaviours, during pregnancy and up to 6 weeks postpartum.
Various techniques for assisting care providers with workflows and handoffs are described. An example method includes identifying patient data that includes message data, electronic medical record (EMR) data, and sensor data. The message data includes at least one text, audio, or video message about a patient. The EMR data includes at least a portion of an EMR of the patient. The sensor data includes at least one image the patient detected by a camera mounted on a hospital bed on which the patient is supported. The example method further includes determining, based on the patient data, a condition of the patient and a task associated with the patient. A report including the condition of the patient and the task is generated and transmitted to a computing device associated with the care provider.
The invention provides methods and composiitons relating to an I.KAPPA. B kinase, IKK-.alpha., and related nucleic acids. The polypeptides may be produced recombinantly from transformed host cells from the disclosed IKK-.alpha. encoding nucleic acids or purified from human cells, The invention provides isolated IKK-.alpha. hybridization probes and primers capable of specifically hybridizing with the disclosed IKK-.alpha. genes, IKK-.alpha.-specific binding agents such as specific antibodies, and methods of making and using the subject compositions in diagnosis, therapy and in the biopharmaceutical industry.
This is a one-site, non-dispensing clinical trial using the Apioc contact lens design. This soft contact lens study will determine the feasibility of this design by determining which parameters of the shape of the Apioc Contact Lens design will yield a successful fit across subjects. We will also determine the percentage of subjects who can be successfully fitted with the Apioc Contact Lens Design. Because the feasibility of the lens design may be dependent upon age, a total of 50 subjects (10 subjects each across 5 decades of life) will complete the study. The data will be collected in a single visit for most subjects. A few subjects may be asked to return for a second visit if additional contact lens parameters need to be ordered to achieve a successful fit. The key assessments for this study will be demonstration of feasibility of fit, documentation of movement in all gazes, including translation, and subjective reports of comfort. Subjects will only wear contact lenses while in the office.
INTRODUCTION: Evidence about nefroprotective effect with RAAS blockers in elderly patients with chronic kidney disease (CKD) without proteinuria is lacking. The primary outcome of our study is to evaluate the impact of RAAS blockers in CKD progression in elderly patients without proteinuria.
MATERIALS AND METHODS: Multicenter open-label, randomized controlled clinical trial including patients over 65 year-old with hypertension and CKD stages 3-4 without proteinuria. Patients were randomized in a 1:1 ratio to either receive RAAS blockers or other antihypertensive drugs and were followed up for three years. Primary outcome is estimated glomerular filtration rate (eGFR) decline at 3 years. Secondary outcome measures include BP control, renal and cardiovascular events and mortality.
RESULTS: 88 patients were included with a mean age of 77.9±6.1 years and a follow up period of 3 years: 40 were randomized to RAAS group and 48 to standard treatment. Ethiology of CKD was: 53 vascular, 16 interstitial and 19 of unknown ethiology. In the RAAS group eGFR slope during follow up was -4.3±1.1ml/min, whereas in the standard treatment group an increase on eGFR was observed after 3 years (+4.6±0.4ml/min), p=0.024. We found no differences in blood pressure control, number of antihypertensive drugs, albuminuria, potassium serum levels, incidence of cardiovascular events nor mortality during the follow up period.
CONCLUSIONS: In elderly patients without diabetes nor cardiopathy and with non proteinuric CKD the use of RAAS blockers does not show a reduction in CKD progression. The PROERCAN (PROgresión de Enfermedad Renal Crónica en ANcianos) trial (trial registration: NCT03195023).
The embodiment of the application provides a sending device, an electronic terminal and a method for transmitting information of a doctor. The method comprises the steps of transmitting information in a wireless communication mode, determining each electronic terminal located in a preset safe distance range by sending a distance detection signal in the transmission process, and determining the electronic terminal receiving the treatment information by exchanging authentication information to each electronic terminal. Common theft devices or theft means cannot steal information transmitted within the secure distance. Privacy information exists in the authentication information, so that privacy protection of the information in the transmission process can be improved by acquiring the authentication information of each electronic terminal within a safe distance range. Thus, after the electronic terminal for receiving the information of the treatment is determined, the treatment information is sent to the target device. The method is used for reducing the situation that information is easy to steal in the transmission process.
After the first test application with the scales specified in the data collection, 8 sessions of Cognitive Behavior Therapy-based psycho-education sessions will be applied to the intervention group. At the end of the 8 sessions (which will last 30 days on average), a final test will be applied.
Slough is a well-known feature of non-healing wounds. This pilot study aims to determine the proteomic and microbiologic components of slough as well as interrogate the associations between wound slough components and wound healing. Ten subjects with slow-to-heal wounds and visible slough were enrolled. Aetiologies included venous stasis ulcers, post-surgical site infections and pressure ulcers. Patient co-morbidities and wound healing outcome at 3-months post-sample collection was recorded. Debrided slough was analysed microscopically, through untargeted proteomics, and high-throughput bacterial 16S-ribosomal gene sequencing. Microscopic imaging revealed wound slough to be amorphous in structure and highly variable. 16S-profiling found slough microbial communities to associate with wound aetiology and location on the body. Across all subjects, slough largely consisted of proteins involved in skin structure and formation, blood-clot formation and immune processes. To predict variables associated with wound healing, protein, microbial and clinical datasets were integrated into a supervised discriminant analysis. This analysis revealed that healing wounds were enriched for proteins involved in skin barrier development and negative regulation of immune responses. While wounds that deteriorated over time started off with a higher baseline Bates-Jensen Wound Assessment Score and were enriched for anaerobic bacterial taxa and chronic inflammatory proteins. To our knowledge, this is the first study to integrate clinical, microbiome, and proteomic data to systematically characterise wound slough and integrate it into a single assessment to predict wound healing outcome. Collectively, our findings underscore how slough components can help identify wounds at risk of continued impaired healing and serves as an underutilised biomarker.
In the intervention arm, the participants will watch a 10 minute recorded educational video demonstrating the use of the trauma checklist prior to their simulation scenario. These teams will subsequently receive a copy of the checklist for use during their simulation scenario.
The invention discloses a novel anti-tumor metastasis polypeptide and application thereof, belonging to the field of medicines. The polypeptide is derived from a partial peptide segment of endogenous HSP90AA1 protein, and specifically discloses that the gene sequence of the polypeptide is SEQ ID NO.1, SEQ ID NO.2 and SEQ ID NO.3, and the corresponding amino acid sequence is SEQ ID NO.4, SEQ ID NO.5 and SEQ ID NO. 6. And the amino acid sequence of the fusion polypeptide is SEQ ID NO.7, SEQ ID NO.8 or SEQ ID NO. 9. The polypeptide can accurately target the anti-tumor metastasis protein NM23-H1, and inhibit the degradation of endogenous anti-tumor metastasis protein NM23-H1 of tumor cells on the nanomolar concentration level, so as to inhibit tumor metastasis, therefore, the polypeptide can be used as a candidate drug for inhibiting tumor metastasis, and has good clinical application value.
The present invention relates to the treatment of inflammatory disorders not only for humans but also for animals, specifically for treating arthritis (inflammatory ankle disease). In the concrete it refers to the use of functional blocking antibody or fragment thereof, which bind to epitope of VLA-1, for preparing pharmaceutical composition for arthritis treatment. It refers to antibodies blocking integrin {alpha}1{beta}1, or fragment of such an antibody. Blocking occurs in such a way, that the antibody or its fragment binds to epitope of VLA-1. The epitope of VLA-1 is formed of amide acid remains 91 to 96 (Val-Gln-Gly-Gly-Arg). The antibody is according to the invention human antibody, chimeric antibody, or humanized antibody and it is both monoclonal and polyclonal antibody.
Combining traditional Chinese medicine theory and modern medical knowledge, this study explores the pathogenesis of sudden hearing loss in middle-aged and young people. Sixty-four young and middle-aged patients with sudden hearing loss who visited a public tertiary hospital in China are chosen as experimental objects. All experimental patients are broken into an experimental group (n = 32) and a control group (n = 32). The control group receive conventional Western medicine treatment regimen. The experimental group receive select acupoint acupuncture and bloodletting combined with Rosenthal effect for psychological intervention, and both groups have a treatment course of 14 days. The changes in the patient's condition before and after treatment are observed, and the differences in hearing threshold values, tinnitus, and dizziness clinical efficacy before and after treatment are observed and recorded. It evaluates the efficacy using the Anxiety, Depression Scale, and Hope Scale and statistically analyzes the data. The dizziness score of the experimental group decreased rapidly, the treatment onset time was shorter, and the improvement effect on dizziness symptoms was better (P < .05). After 1 month of intervention treatment, the intervention of the experimental group was better (P < .05). The hope level and self-efficacy of both groups of patients were raised in contrast with before treatment (P < .05). After 1 month, the intervention effect of the experimental group was more significant (P < .01). Both groups could improve patient ear blood circulation, but the experimental group had lower plasma viscosity, hematocrit, and red blood cell aggregation index, higher red blood cell deformation index, and more significant improvement effect (P < .05). The effective rates of improving hearing and tinnitus in the experimental group reached 87.5% and 81.5%, and the clinical treatment efficacy was better than that in the control group (P < .05). The level of depression and anxiety in the experimental group remained relatively stable, while that in the control group showed a significant rebound (P < .05). In conclusion, both groups had a certain effect in treating sudden deafness, both of which could effectively improve the patient's hearing. But in contrast with the control group, the experimental group had better clinical efficacy, higher safety, and better psychological intervention results, which is worthy of clinical promotion.
A lactase-containing preparation is prepared for use by mammals having a lactase deficiency. A dried bacterial culture containing lactase is mixed with a desiccant such as silicon oxide to stabilize water content of the dried culture. A unit dosage of the resultant stabilized dried bacterial culture is encapsulated in an ingestible capsule such as gelatin capsule. The capsule is coated with an enteric polymer, and the coated capsule is treated under vacuum pressure to remove oxygen and moisture. The treated coated capsule has an extended shelf-life at room and elevated temperatures, and provides lactase activity for at least 10 hours after ingestion. The dried bacterial culture may be in freeze dried form. Suitable bacterial cultures are Lactobacillus acidophillus, Lactobacillus bulgaricus and Streptococcus thermophilus.
PURPOSE: To evaluate range of visual acuity, visual quality, and safety of the IC-8 small-aperture (SA) intraocular lens (IOL) (Apthera; Bausch & Lomb, Inc) in patients with cataract.
METHODS: This was a prospective, multicenter, open-label, parallel-group, non-randomized, examiner-masked, 12-month clinical study conducted at 21 sites in the United States. Included patients (N = 453) received either the SA IOL (targeted to -0.75 diopters) in one eye and a monofocal or monofocal toric IOL (targeted to plano) in the fellow eye (SA IOL group, n = 343) or bilateral monofocal/monofocal toric IOLs (control group, n = 110).
RESULTS: At 6 months, the SA IOL group achieved superior binocular uncorrected intermediate and near visual acuity (P < .0001) and equivalent binocular uncorrected distance visual acuity versus the control group. In SA IOL eyes, 99.1% achieved monocular corrected distance visual acuity of 0.3 logarithm of the minimum angle of resolution or better. The SA IOL and control groups had comparable binocular photopic and mesopic contrast sensitivities at 6 months both with and without glare. The SA IOL group reported few visual symptoms overall, although at higher rates than in the control group.
CONCLUSIONS: The SA IOL group exhibited improved intermediate and near vision, comparable distance vision and binocular contrast sensitivities, and few visual symptoms or adverse events versus the bilateral monofocal/monofocal toric IOL group, suggesting that the SA IOL is an effective option for presbyopia correction at the time of cataract surgery. [J Refract Surg. 2024;40(11):e824-e835.].
A method and system for distributing pharmaceuticals and packages of pharmaceutical products are described. A wholesaler receives an aggregate order for products that includes an indication of individual patient-orders contained within the aggregate order. The wholesaler retrieves the products from stock and packages them in bundles coinciding with the patient-orders to form pharmacist-ready packages. Indicia are applied to each pharmacist-ready package identifying its associated patient-order. A vendor or pharmacy receives the pharmacist-ready packages, verifies the contents thereof using the indicia, labels each of the products therein as required, reseals the products in the package, and applies a package label associated with a patient for which the patient-order was placed. The package label is disposed to overlie the indicia. The now patient-ready package is provided to the patient. As such, need for stocking, retrieval from stock, and grouping of products by the pharmacy is reduced.
Circulating tumor cells (CTCs) are tumor cells that separate from the solid tumor and enter the bloodstream, which can cause metastasis. Detection and enumeration of CTCs show promising potential as a predictor for prognosis in cancer patients. Furthermore, single-cells sequencing is a technique that provides genetic information from individual cells and allows to classify them precisely and reliably. Sequencing data typically comprises thousands of gene expression reads per cell, which artificial intelligence algorithms can accurately analyze. This work presents machine-learning-based classifiers that differentiate CTCs from peripheral blood mononuclear cells (PBMCs) based on single cell RNA sequencing data. We developed four tree-based models and we trained and tested them on a dataset consisting of Smart-Seq2 sequenced data from primary tumor sections of breast cancer patients and PBMCs and on a public dataset with manually annotated CTC expression profiles from 34 metastatic breast patients, including triple-negative breast cancer. Our best models achieved about 95% balanced accuracy on the CTC test set on per cell basis, correctly detecting 133 out of 138 CTCs and CTC-PBMC clusters. Considering the non-invasive character of the liquid biopsy examination and our accurate results, we can conclude that our work has potential application value.
BACKGRUOUND: Diabetes-induced cardiac fibrosis is one of the main mechanisms of diabetic cardiomyopathy. As a common histone methyltransferase, enhancer of zeste homolog 2 (EZH2) has been implicated in fibrosis progression in multiple organs. However, the mechanism of EZH2 in diabetic myocardial fibrosis has not been clarified.
METHODS: In the current study, rat and mouse diabetic model were established, the left ventricular function of rat and mouse were evaluated by echocardiography and the fibrosis of rat ventricle was evaluated by Masson staining. Primary rat ventricular fibroblasts were cultured and stimulated with high glucose (HG) in vitro. The expression of histone H3 lysine 27 (H3K27) trimethylation, EZH2, and myocardial fibrosis proteins were assayed.
RESULTS: In STZ-induced diabetic ventricular tissues and HG-induced primary ventricular fibroblasts in vitro, H3K27 trimethylation was increased and the phosphorylation of EZH2 was reduced. Inhibition of EZH2 with GSK126 suppressed the activation, differentiation, and migration of cardiac fibroblasts as well as the overexpression of the fibrotic proteins induced by HG. Mechanical study demonstrated that HG reduced phosphorylation of EZH2 on Thr311 by inactivating AMP-activated protein kinase (AMPK), which transcriptionally inhibited peroxisome proliferator-activated receptor γ (PPAR-γ) expression to promote the fibroblasts activation and differentiation.
CONCLUSION: Our data revealed an AMPK/EZH2/PPAR-γ signal pathway is involved in HG-induced cardiac fibrosis.
INTRODUCTION: Typical antipsychotics are known to produce extrapyramidal side effects such as drug induced parkinsonism, acute dystonia, akathisia, tardive dyskinesias and rabbit syndrome. Rabbit syndrome is characterized by vertical rhythmic motion of the mouth and lips, resembling chewing movements of a rabbit.
REASON FOR THE REPORT: Rabbit syndrome seen in patients on antidopaminergic therapies is characterized by vertical rhythmic movements of perioral region, has a late onset, and characteristically spares the tongue. The main aim of the report is to highlight atypical manifestation of antipsychotic associated Rabbit syndrome in the presence of a serotonergic antidepressant. An elderly patient presented with atypical rabbit syndrome with relatively acute onset, horizontal movements of jaw and marked tongue involvement after haloperidol-escitalopram initiation.
OUTCOME: The patient improved with discontinuation of antipsychotic. The tongue involvement was believed to be secondary to escitalopram use.